Consideraes finais sobre a Retatrutida, Semaglutida e Tirzepatida As medicaes Retatrutida, Semaglutida e Tirzepatida so avanos promissores no tratamento da obesidade
Recent data are still highly polarized, with some authors supporting (255), and others disproving this (256), or even indicating that GPR40 protects -cells from lipotoxicity (257) rendering difficult to draw any conclusive mechanistic involvement in healthy and diabetic individuals
and international guidelines are rapidly evolving to address the risks associated with GLP-1 use
Treatment stage What may be common What deserves attention Week 1 Nausea, fullness, reduced appetite, bloating, indigestion, diarrhea, constipation, fatigue Repeated vomiting, severe pain, inability to stay hydrated Weeks 2 to 4 Early symptoms may settle, persist, or fluctuate Symptoms interfering with eating, drinking, or daily function Weeks 5 to 8 Symptoms may reappear after clinician-directed dose escalation A significant return or worsening of gastrointestinal symptoms Months 2 to 3 Some patients tolerate treatment more comfortably
